Pulmatrix, Inc.

Pulmatrix, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Pulmatrix, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Pulmatrix, Inc..
Log in to see more information.
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and develo...
PULM Fundamental Data by TradingView

News

Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com
Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

Ticker Report Analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM - Get Free Report) in a report released on Saturday. The brokerage set a "hold" rating on the biotechnology company's...\n more…

Pulmatrix (NASDAQ:PULM) Receives New Coverage from Analysts at StockNews.com
Pulmatrix (NASDAQ:PULM) Receives New Coverage from Analysts at StockNews.com

Ticker Report Stock analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM - Get Free Report) in a research report issued on Friday. The firm set a "hold" rating on the biotechnology...\n more…

Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com
Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

Ticker Report StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM - Free Report) in a research note released on Thursday. The firm issued a hold rating on the biotechnology company's stock. Pulmatrix...\n more…

Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)
Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)

Simply Wall St Pulmatrix ( NASDAQ:PULM ) Second Quarter 2024 Results Key Financial Results Revenue: US$1.55m (down 16% from 2Q 2023...\n more…

Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com
Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com

Zolmax Equities researchers at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM - Get Free Report) in a report released on Wednesday. The brokerage set a "hold" rating on the biotechnology...\n more…

StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)
StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)

Ticker Report StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM - Get Free Report) in a research note issued on Wednesday. The brokerage set a "hold" rating on the biotechnology company's stock...\n more…